Marvin & Palmer Associates Inc. Takes $7.13 Million Position in iShares Biotechnology ETF $IBB

Posted by George Bondi on Jun 10th, 2026

Marvin & Palmer Associates Inc. acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 42,219 shares of the financial services provider’s stock, valued at approximately $7,125,000. iShares Biotechnology ETF makes up 5.0% of Marvin & Palmer Associates Inc.’s portfolio, making the stock its 7th largest position. Marvin & Palmer Associates Inc. owned about 0.09% of iShares Biotechnology ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in IBB. BNP Paribas Financial Markets lifted its position in shares of iShares Biotechnology ETF by 313.2% in the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after acquiring an additional 1,451,820 shares in the last quarter. WestEnd Advisors LLC purchased a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at about $106,276,000. Truist Financial Corp lifted its position in shares of iShares Biotechnology ETF by 2,239.6% in the fourth quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock valued at $108,354,000 after acquiring an additional 614,582 shares in the last quarter. LPL Financial LLC lifted its position in shares of iShares Biotechnology ETF by 145.9% in the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after acquiring an additional 589,033 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in shares of iShares Biotechnology ETF in the third quarter valued at about $65,083,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $169.36 on Wednesday. The stock’s 50-day simple moving average is $170.16 and its 200-day simple moving average is $170.62. iShares Biotechnology ETF has a 52 week low of $123.61 and a 52 week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were given a $0.1218 dividend. This represents a $0.49 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Tuesday, March 17th.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.